Selected data models

You must log in to select data models for download or further analysis.

25 Search results.
Relevance Rating New first Old first

Eligibility Basal Cell Carcinoma NCT01327053

- 9/27/21 - 1 form, 3 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria, Other inclusion/exclusion criteria
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01327053 Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals )

Eligibility Skin Cancers NCT01108094

- 9/18/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas; ODM derived from: https://clinicaltrials.gov/show/NCT01108094

Eligibility Nodular Basal Cell Carcinoma NCT02018679

- 8/18/21 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Basal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02018679

Eligibility Nodular Basal Cell Carcinoma NCT01808950

- 7/28/21 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC); ODM derived from: https://clinicaltrials.gov/show/NCT01808950

Vismodegib for Basal Cell Carcinoma NCT01631331 - Eligibility Criteria

- 6/1/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Vismodegib in Treating Patients With Basal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01631331 Brief Summary: The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.

Eligibility Carcinoma, Basal Cell NCT02436408

- 2/16/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
VISmodegib for ORbital and Periocular Basal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02436408

Eligibility Basal Cell Carcinoma NCT02296970

- 2/1/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Observational Study to Determine the Clinical Cure Rate of Therapeutic up Front Shave Removal of Basal Cell Carcinoma of the Skin With Long Term Follow up to Evaluate Recurrence; ODM derived from: https://clinicaltrials.gov/show/NCT02296970

Eligibility Superficial Basal Cell Carcinoma NCT01491711

- 1/22/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate; ODM derived from: https://clinicaltrials.gov/show/NCT01491711

Eligibility Superficial Basal Cell Carcinoma NCT00994240

- 11/4/18 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC; ODM derived from: https://clinicaltrials.gov/show/NCT00994240

Eligibility Basal Cell Carcinoma NCT01898598

- 10/10/18 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01898598 Sponsor: Hoffmann-La Roche Information provided by (Responsible Party): Hoffmann-La Roche Study Director: Clinical Trials Hoffmann-La Roche

Eligibility Basal Cell Carcinoma NCT02059252

- 10/9/18 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold; ODM derived from: https://clinicaltrials.gov/show/NCT02059252 Collaborating Parties: Welsh Centre for Burns and Plastic Surgery, Swansea, UK Queen Victoria Hospital NHS Foundation Trust

Eligibility Basal Cell Carcinoma NCT01298167

- 10/9/18 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Absorbable Suture Versus Tissue Glue to Repair Defects Following Mohs Surgery; ODM derived from: https://clinicaltrials.gov/show/NCT01298167

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial